Gastro-retentive drug delivery technologies and their applications with cardiovascular medications

Many trials have recently been conducted to increase drug absorption and the efficacy of oral dose formulations (DFs). Various technologies have been developed in recent years to solve physiological obstacles such as changes in gastric retention and emptying time by researching and developing controlled-release oral medication delivery systems. To develop therapeutic drug efficacy, medicines that display a window type of absorption, have stability problems at basic pH, have high solubility in the acidic environment, or which are locally active in the gastric medium can be loaded into gastroretentive drug delivery systems (GRDDSs). For the past three decades, (GRDFs) have been developed. Historically, they were intended for veterinary medicine, but the design was later modified to improve human medication treatment. Sustained oral-release Gastroretentive dosage forms have several benefits for pharmaceuticals which are absorbed through the upper gastrointestinal system, and they increase the bioavailability of treatments with a narrow absorption window. Expandable systems, mucosal adhesive systems, ultra-porous floating systems, high-density systems, magnetic systems, and hydrogels, are among the strategies described in this review to lengthen stomach residency time. The current study discusses some cardiovascular medications that could benefit from gastroretentive methods, as well as the elements that determine gastric retaining time and how gastroretentive systems work.